Patients that are having Covid-19 Disease After the First Dose of Covid-Vaccine

Hakan Sezgin Sayiner, Aşki Vural, Fatih Doğan, Sedat Parlak, Furkan Bakirhan


There is no effective treatment for the Covid-19 disease that is still impacting the whole world. It considered that vaccines, one of the effective means to prevent infectious diseases, will play a significant role in protecting from the Covid-19 Disease. Vaccinations generals performed before exposure. We aimed to follow the clinical and laboratory progress of patients who got Covid-19 after the first dose of the Covid-19 vaccine and to evaluate the changes that may occur in antibody formation. 13 patients, who received the first dose of COVID 19 vaccine Coronovac as of 14.01.2021 when vaccination started in Adıyaman University Training and Research Hospital/Turkey, who had symptoms after the vaccine and whose real-time PCR found to be positive, were included in the study. After the first dose of the Covid-19 vaccine, 13 patients exam. Three of our patients were female, and 10 of them were male. The average age was 38.8. British variant detected in 4 of our patients; 1 of them was female. Contact times differed between 3 and 5 days. The most common symptoms were muscle-joint pain (53.8), weakness-fatigue (46.2), fever (38.5), and headache (30.8). Three of our patients, being one female, received inpatient treatment. Furthermore, our five patients who checked regarding Sars cov-2 IgG became positive in the first month. No adverse changes in the course of the illness observed in the patients were RT-PCR positive after the first dose of the Covid-19 vaccine. Antibody response detected at the end of the first month.  Vaccination is an effective method for taking infectious diseases under control but adhering to personal protective measures still maintains their importance.


Covid-19 disease; Covid-19 vaccine; Reverse Transcription-Polymerase Chain Reaction (RT-PCR)

Full Text:



Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O'Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. (2020). Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020 Apr 27, ciaa478. doi: 10.1093/cid/ciaa478.

Dong, L., Hu, S., & Gao, J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics, 14(1), 58-60.

Gallagher, T., & Lipsitch, M. (2019). Postexposure effects of vaccines on infectious diseases. Epidemiologic reviews, 41(1), 13-27.

Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Zhong, N. S. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine, 382(18), 1708-1720.

Henderson, D. A., Inglesby Jr, T. V., O'Toole, T., & Mortimer, P. P. (2003). Can postexposure vaccination against smallpox succeed?. Clinical Infectious Diseases, 36(5), 622-629.

Jin, Z., Du, X., Xu, Y. et al. (2020). Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature, 582, 289–293.

Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., & Lessler, J. (2020). The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine, 172(9), 577-582.

Lee, Y. H., Hong, C. M., Kim, D. H., Lee, T. H., & Lee, J. (2020). Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerging infectious diseases, 26(10), 2346.

Lim, H. X., Lim, J., Jazayeri, S. D., Poppema, S., & Poh, C. L. (2020). Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomedical Journal.

Massoudi, M. S., Barker, L., & Schwartz, B. (2003). Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. The Journal of infectious diseases, 188(7), 973-976.

Onsun N, Kaya G, Işık BG, Güneş B. (2021). A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report. Health Promot Perspect; 11(2),261-262. doi:10.34172/hpp.2021.32

Rawat, K., Kumari, P., & Saha, L. (2020). COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. European journal of pharmacology, 173751.

Sheppeard, V., Forssman, B., Ferson, M. J., Moreira, C., Campbell-Lloyd, S., Dwyer, D. E., & McAnulty, J. M. (2009). The effectiveness of prophylaxis for measles contacts in NSW. New South Wales public health bulletin, 20(6), 81-85.

Soiza, R. L., Scicluna, C., & Thomson, E. C. (2021). Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing, 50(2), 279-283.

Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. (2021). Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. The Lancet, 398(10296), 213–22. Available from:

Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., & Riley, S. (2019). S.[van Elsland], E. Volz, H. Wang, Y. Wang, X. Xi, CA Donnelly, AC Ghani, NM Ferguson, Estimates of the severity of coronavirus disease, 30243-7.

Xu, X. W., Wu, X. X., Jiang, X. G., Xu, K. J., Ying, L. J., Ma, C. L., & Li, L. J. (2020). Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. bmj, 368.


  • There are currently no refbacks.